Konzept einer komplexen Tumortherapie mit kurativem Anspruch auch in fortgeschrittenen Stadien

Zusammenfassung

In diesem Beitrag geht es um einen onkologischen Behandlungskomplex, der eine Integration und kompatible Adaptation von komplementären naturheilkundlichen Behandlungsmethoden und neuen Behandlungsformen wie PAMP-Therapie und Checkpoint-Inhibitoren sowie einigen Elementen konventioneller Therapien enthält. Dabei wird besondere Aufmerksamkeit auf die Kompatibilität der unterschiedlichen Behandlungsformen und die Therapiesicherheit sowie die Vermeidung von Arzneimittelinteraktionen gelegt. Die Behandlungsmethode und der Verlauf der Genesung werden in komprimierter Form anhand von praktischen Fallbeispielen dargestellt.

Abstract

This article is about an oncological treatment complex that comprises an integration and compatible adaptation of complementary naturopathic treatment methods and new forms of treatment such as PAMP therapy and checkpoint inhibitors, as well as some elements of conventional therapies. Here, special attention is paid to the compatibility of the different forms of treatment and therapeutic safety as well as avoidance of drug interactions. The treatment method and the course of recovery are presented in a condensed form with the help of practical case studies.

Schlüsselwörter

komplexe Tumortherapie - Krebs - Komplementärmedizin - PAMP-Therapie - Checkpoint-Inhibitoren

Key words

complex tumor therapy - cancer - complementary medicine - PAMP therapy - checkpoint inhibitors

Publication History

Article published online:
10 August 2023

• Literatur

• 1 Hanahan D, Coussens LM. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21 (03) 309-322
• 2 Dupré de Lisle. Treatise on the cancer disease. Paris: Couturier; 1774
• 3 Coley WB. The treatment of malignant tumours by repeadete inoculations of erysipelas; with a report of 10 original cases. Am J Med Soc. 1893
• 4 Coley Nauts H. The beneficial effects of bacterial infections on host resistance to cancer end redults in 449 cases. Im Internet: Accessed June 15, 2023 at: https://www.cancerresearch.org/wp-content/uploads/2022/10/CRI_media_HCN-Monographs_8_THE-BENEFICIAL-EFFECTS.pdf_ext.pdf
• 5 Huth EF. Zum Antagonismus zwischen bakteriellen Infektionen und malignen Erkrankungen. Med Klin 1958; 53: 2173-2177
• 6 Hobohm U, Stanford JL, Grange JM. Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol. 2008 DOI: 10.1615/critrevimmunol.v28.i2.10
• 7 Sharma P, Stecklein SR, Yoder R. et al. Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC). J Clin Oncol. 2022 DOI: 10.1200/JCO.2022.40.16_suppl.513
• 8 Demaria S, Ng B, Devitt ML. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004 DOI: 10.1016/j.ijrobp.2003.09.012
• 9 Postow MA, Callahan MK, Barker CA. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 DOI: 10.1056/NEJMoa1112824
• 10 Kulzer L, Rubner Y, Deloch L. et al. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol. 2014 DOI: 10.3109/1547691X.2014.880533
• 11 Theelen WSME, Peulen HMU, Lalezari F. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer. JAMA Oncol. 2019 DOI: 10.1001/jamaoncol.2019.1478
• 12 Plate JM, Plate AF, Shott S. et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005 DOI: 10.1007/s00262–004–0638–1
• 13 Peters S, Rizvi N, Kuzioraet M. et al. Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1 L metastatic (m) NSCLC: Analyses from the Phase 3 MYSTIC trial. 35. Berlin: Deutscher Krebskongress; 13.–16.11 2022
• 14 Rudin CM, Poirier JT, Byers LA. et al. Molekulare Subtypen von kleinzelligem Lungenkrebs: Eine Synthese von Human- und Mausmodelldaten. Nat Rev Cancer 2019; 19 (05) 289-297